santé – Accès aux traitements innovants relatifs aux mutations du cancer du poumon

This written question asks about improving access to new treatments for lung cancer patients with specific genetic mutations. It highlights the need for timely availability of these innovative therapies. The question seeks to understand how to ensure patients can benefit from these advanced treatments, potentially impacting healthcare providers and pharmaceutical companies.